title: [Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids].
abstract: METHODS
  A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness.
  
  
  CONCLUSIONS
  Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME.
authors.affiliation: Consorcio Hospital General Universitario de Valencia, Valencia, España.
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: L
authors.initials: L
authors.lastname: Amselem
authors.forename: E
authors.initials: E
authors.lastname: Cervera
authors.forename: S
authors.initials: S
authors.lastname: García-Delpech
authors.forename: C
authors.initials: C
authors.lastname: Torralba
authors.forename: J
authors.initials: J
authors.lastname: Montero
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004351:Drug Resistance; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000188:drug therapy*; D019591:Pseudophakia / Q000150:complications; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide